Dasatinib
- PDF / 169,970 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 49 Downloads / 118 Views
1
S
Pleural effusion: case report A man in his early 80s [exact age at the time of reaction onset not stated] developed pleural effusion during treatment with dasatinib for Philadelphia-chromosome positive acute lymphoblastic leukaemia. The man presented to the haematology department with pain in the left hypochondrium and was admitted with a diagnosis of acute lymphoblastic leukaemia at the age of 72 years. On day 1 of admission, he started receiving treatment with dasatinib [initial dosage and route not stated]. However, the treatment was stopped on day 9 of admission due to intestinal perforation [aetiology not stated]. Later, oral dasatinib 70 mg/day was re-started for 22 days as an induction therapy and he achieved a complete remission with negative minimal residual disease. The dose was gradually increased to reach 140 mg/day, and he achieved a complete molecular and haematological remission. The remission persisted for 7 years. Later, the dose of dasatinib was reduced to 100 mg/day for dyspnoea [aetiology not stated] without pleural effusion. Three years later, he was re-hospitalised to the internal medicine due to iatrogenic pleural effusion and deterioration of his clinical condition. Therefore, the man voluntarily discontinued dasatinib treatment. During follow-up visit after 2 years, he maintained complete molecular and haematological remission [outcome not stated]. Author comment: "Three years after hospitalization in internal medicine for iatrogenic pleural effusion and deterioration of clinical conditions." Greve MB, et al. Treatment free remission in philadelphia chromosome-positive acute lymphoblastic leukemia: A case report. Haematologica 104 (Suppl. 2): 172 abstr. PU48, Oct 2019. Available from: URL: http://www.haematologica.org/ 803433831 content/104/s2/1.full.pdf+html [abstract] - Italy
0114-9954/19/1779-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 16 Nov 2019 No. 1779
Data Loading...
